The role of antifungals in the management of patients with severe asthma

Table 3 Asthma pricing—biologics

Product	Company	Target	Year of market licensing	Price of 6 months treatment
Product	Company	Target	Year of market licensing	USA (USD)	UK (USD)	France (USD)
Xolair (omalizumab)	Roche/Novartis	IgE	2003	21.2 K	17.4 k	20.5 K
Nucala (mepolizumab)	GSK	IL-5	2015	19.2 K	7.2 K	7.3 K
Cinqair/Cinqaero (reslizumab)	Teva	IL-5	2016	17.4 K	8.4 K	n/a
Fasenra (benralizumab)	AstraZeneca / Kyowa Hakko Kirin	IL-5R	2017	19.2 K	16.6 K	14.4 K
Dupixent (dupilumab)	Sanofi-Genzyme Regeneron	IL-4 IL-13	2018	21.1 K	10.8 K	10.4 K

n/a, not applicable
Sources: RedBook Online, accessed Jan 2020 [94]; MIMS Online, accessed Jan 2020 [95]; Akuthota and Weller UpToDate, 2018 [96]
Note: The US price is the wholesale acquisition cost (WAC), which is the manufacturer's list price for a product when sold to wholesalers. The WAC may not represent actual transaction prices and does not include discounts or rebates Assumptions: Exchange rate of £1:$1.30, €1:$1.20
US Prescribing Information and European SPCs; RedBook Online, accessed Feb 2019 [94]; MIMS Online, accessed Feb 2019 [95]
Xolair dose depends on body weight and pre-treatment IgE serum levels. The US price is the wholesale acquisition cost (WAC), which is the manufacturer’s list price for a product when sold to wholesalers. The WAC may not represent actual transaction prices and does not include discounts or rebates Assumptions: (1) average body weight of 75 kg; (2) no sharing of vials between patients; (3) exchange rate of £1:$1.29, XE, com, Feb 2019

ISSN: 2045-7022